Related Experiment Video
Updated: Aug 7, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Dilated cardiomyopathy in children
1Department of Cardiology, Ospedale Pediatrico Bambino Gesù, Scientific Institute, (IRCCS), Rome, Italy. gagliard@opbg.net
Insights
Short-term immunosuppression improved long-term survival in children with myocarditis, a rare pediatric disease. This treatment approach for pediatric myocarditis shows promising results compared to conventional methods.
Area of Science:
- Pediatric Cardiology
- Immunology
- Cardiovascular Research
Background:
- Dilated cardiomyopathy (DCM) is uncommon in children.
- Autoimmunity is implicated in the development of myocarditis.
- Myocarditis in children requires effective treatment strategies.
Purpose of the Study:
- To analyze the epidemiology and clinical features of pediatric myocarditis.
- To evaluate the role of immunotherapy in treating childhood myocarditis.
- To assess the long-term survival rates following immunosuppressive therapy.
Main Methods:
- Retrospective analysis of pediatric myocarditis cases.
- Application of immunosuppressive therapy in affected children.
- Comparison of survival rates with historical conventionally treated groups.
Main Results:
- Immunosuppressive therapy was associated with high long-term survival rates in children with myocarditis.
- This survival rate contrasts with lower rates in previously published conventionally treated pediatric series.
- The study suggests a potential distinct pathological entity for DCM with myocarditis.
Conclusions:
- Short-term immunosuppression appears beneficial for long-term survival in pediatric myocarditis.
- This treatment strategy offers a significant improvement over conventional care for childhood myocarditis.
- Further research into prognostic markers is needed to guide treatment decisions.
Unlabelled:
Dilated cardiomyopathy (DCM) is a rare disease in the paediatric population. We analysed the epidemiology, clinical features and role of immunotherapy in the treatment of myocarditis. On the basis of experimental evidence, indicating that autoimmunity might play a role in the development of myocarditis, we treated children affected by myocarditis with immunosuppressive therapy, and we present here our series. The future availability of reliable prognostic markers should allow treatment of only those children with myocarditis who do not spontaneously recover. The possibility that DCM with myocarditis is a distinct pathological entity from the non-inflammatory form of DCM is suggested.
Conclusion:
The high long-term survival rate observed in our children with myocarditis is probably due to the effect of short-term immunosuppression. This result is at odds with previously published series of conventionally treated children, whose survival probability at 1 y was approximately 0.60.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy IV: Restrictive Cardiomyopathy
Imbalances in Cardiac Output
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...

